CN105943618A - Drug for treating depression - Google Patents
Drug for treating depression Download PDFInfo
- Publication number
- CN105943618A CN105943618A CN201610415926.6A CN201610415926A CN105943618A CN 105943618 A CN105943618 A CN 105943618A CN 201610415926 A CN201610415926 A CN 201610415926A CN 105943618 A CN105943618 A CN 105943618A
- Authority
- CN
- China
- Prior art keywords
- depression
- industrial hemp
- medicine
- fructus cannabis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug for treating depression. The drug is prepared by evenly mixing 0.3-99.7 parts by weight of industrial hemp seed extract and 99.7-0.3 parts by weight of industrial cannabinoid. It is proved through experiments that the drug can significantly shorten the tail suspension immobilization time of mice of a behavioral despair depression model and significantly shorten immobility time of forced swimming, has an obvious anti-depressant effect on a mouse depression model caused by reserpine and can significantly increase the frequency of spontaneous activities of the mice, and the effects are all superior to those of cannabidiol. The drug can be used for preparing drugs for treating various depression symptoms including endogenous depression, reactive depression, masked depression, secondary depression caused by drugs, climacteric or postnatal depression, depression caused by cerebral trauma or cerebral apoplexy, diabetes combined depression and depressive neurosis and used for preparing drugs for treating symptoms such as secondary learning memory decline and anhedonia caused by depression.
Description
Technical field
The invention belongs to treating depression drug world, concretely relate to a kind of based on industrial hemp
Want the pharmaceutical composition treating depression prepared by raw material.
Background technology
The plantation of Fructus Cannabis is with a long history, ancient times Fructus Cannabis be mainly used in fabrication and processing rope, fishing net, clothing and
Paper making raw material, and oils and fats, food etc..Development and progress along with society, it has been found that contain in Fructus Cannabis
Having a kind of toxic component (tetrahydrocannabinol) that people can be made to cause unreal addiction, American-European many countries are once considerably long
Forbid cultivating in period Fructus Cannabis.Owing to the economic use value of Fructus Cannabis is high, to the eighties in 20th century, some Europe
Low toxicity Hemp Varieties the plantation that puts it over have been cultivated in the research of continent country.Nineteen ninety, the European Community took the lead in promptly
Revision agricultural policy, has abolished the ban of Fructus Cannabis of forbidding cultivating, has started to recover the production of Fructus Cannabis and research.Subsequently
The states such as the U.S., Canada, Australia relieve Fructus Cannabis plantation ban, the whole world Fructus Cannabis cultivated area and
Fiber production has had and has increased rapidly, and the exploitation of industrial hemp are started by American-European countries again, international city
The demand of ecological Fructus Cannabis is also being increased rapidly by field.According to the economic attribution of Fructus Cannabis, for making full use of it it is
The mankind service, and within 1988, the United Nations's clear stipulaties does not possess extraction toxic component (tetrahydrocannabinol THC)
It is worth or sucks directly as drugs, specializing in the raw material Fructus Cannabis of industrial use, industrial hemp (its growth
Tetrahydrocannabinol content in phase Fructus Cannabis floral leaf is less than 0.3%), legal can carry out implantation in large scale and work
Industryization develops.
Industrial hemp be show unique characteristics, living resources that comparative advantages are prominent.Industrial hemp and conventional toxic
Fructus Cannabis has essential distinction, and industrial hemp is the raw material of industry product of a class Non-toxic, has high warp
Ji value.Successively 25 industrial hemp kinds are selected altogether to countries in the world at the end of 2003, and
And seven states such as the method for European Union, moral, English the most all become industrial hemp and mainly plant manufacturing country, with industrial hemp
Fiber and fiber crops seed and flower thereof, leaf, root, stem are that raw material carries out series of products research and development and industrialization comprehensive exploitation,
Industrial hemp primary process major product jute skin fiber, stalk core fibre, hemp seed oil fat and seed cake protein,
On the basis of medicinal standard extract realizes industrialization production, carry out deep processing and utilization further, derive from
Product out has reached more than 25,000 kinds, contain the clothing of the mankind, food, shelter, row, with each greatly
Series products.The research of industrial hemp industry, develop and production is concentrated mainly on Europe, Canada, the U.S.
Etc. technology developed country.The development of industrial hemp industry, is first nontoxic from selection-breeding or the low industry poisoned
Fructus Cannabis new varieties start, and achieve the plantation of scale and combining of hi-tech industrialization based on this
Close and develop, define one " emerging pollution-free industry group " and the quick growth point of infant industry economy.
Fructus Cannabis is Fructus Cannabis dry mature fruit, is generally used as medicine by Fructus Cannabis ancient times, and dietetic therapy is the most on the books.
Fructus Cannabis is included in " being medicine and food " " medicine-food two-purpose " list by health ministry.
The property of medicine of Fructus Cannabis and pharmacology be: sweet, flat.Return spleen, stomach, large intestine channel.Function cures mainly: moisturize, sliding
Intestinal, treating stranguria, invigorate blood circulation.Control dryness of the intestine constipation, quench one's thirst, pyretic stranguria, migratory arthralgia, dysentery.Menoxenia, scabies,
Tinea leprosy.Those benefits in detail is had to record in medical book, such as " herbal classic ": " invigorating the spleen and replenishing QI.”；Tang Materia Medica: " main
Five kinds of over strain.”；" Handbook of Prescriptions for Emergencies ": " control extreme thirst, day eclipse number bucket, hot urination person: pockmarks one liter, three liters of water,
Boiling three, four boilings, extracting juice drinks it.”；" Japan hanako materia medica ": " qi-restoratives labor, long muscle, stimulating milk secretion, only disappear
Yearningly, expedite the emergence of.Control perverse and unreasonable manner to produce.”；Supplement to the Herbal: " therapeutic method to keep the adverse QI flowing downwards, diuresis, go migratory arthralgia skin stupid, fries order
Perfume (or spice) is smashed to pieces, urine leaching juice clothes；Married woman's footling presentation gulps down two or seven pieces.”；" Treatise on Dietetic Therapy ": " extracting juice is cooked congee,
Go the five internal organs wind, lung moistening.Control that joint is obstructed, deal with, promoting blood circulation.”.
The equal hyoscine of floral leaf of Fructus Cannabis.The property of medicine of Folium Cannabis and pharmacology be: pungent；Poisonous.Return lung；Bladder；
Large intestine channel.Function cures mainly: pain relieving, and Dingchuan drives ascarid.Cure mainly asthma, fall and flutter pain, ascariasis.Fiber crops
The property of medicine and the pharmacology of flower be: bitter；Pungent；Warm in nature；Poisonous.Function cures mainly: dispel the wind；Invigorate blood circulation；Hair growth promoting.
Main air disease numb limbs and tense tendons；Pruritus all over；Women's amenorrhea.
Depression is to endanger the modal mental sickness of human physical and mental health now, and its sickness rate accounts for people from world
About the 5% of mouth.Severely impact the healthy of the mankind and quality of life.Expect the year two thousand twenty, press down
Strongly fragrant disease will be the harm human health short-life second largest disease of contracting.
At present, the mechanism of action of antidepressant drug illustrates the most completely.The medicine having clear and definite curative effect is made substantially
For teleneuron synapses, play treatment make by the level of regulation synaptic space neurotransmitter
With.Its etiologic etiological Biochemical Research shows that depression is main and maincenter 5-hydroxy tryptamine (5-HT), nor-kidney
Upper parathyrine (NA), dopamine (DA), acetylcholine (Ach) and γ-aminobutyric acid (GABA) etc. 5
Plant neurotransmitter to be correlated with.
Antidepressants can be divided into non-selective antidepressants in early days and the suppression of new selective reuptake
The big class of agent two.Non-selective antidepressants mainly include oxidase inhibitor (MAOIs) and three rings
Class antidepressants (TCAs)；Selectivity reuptake inhibitor mainly has (1) selectivity 5-hydroxy tryptamine (5-HT)
Reuptake inhibitor (SSRIs), such as fluoxetine (Fluoxetine), paroxetine (Paroxetine).
(2) norepinephrine (NA) reuptake inhibitor (NRIs), such as reboxetine (Reboxitine).
(3) norepinephrine energy and specificity 5-HT reuptake inhibitor (NDRIs), such as mirtazapine
(Mirtazapine).(4) 5-HT and NA dual reuptake inhibitor (SNRIs), such as venlafaxine
And duloxetine (Duloxetine) (Venlafaxine).(5) 5-HT re-absorption accelerator, such as thiophene
Nai Puting (Tianeptine) etc..
Although existing many antidepressants are for clinic, but some drugs is low because of its response rate, and has latent
Side effect, still have suitable patient invalid through various Drug therapys, some demands help electrofit and control
Treat.Therefore, the exploitation of antidepressants is still the focus of new drug research, in China, innovates for antidepressant
The research and development of medicine is also in the starting stage, especially for acting on 5-HT, NA and DA system
The research of novel antidepressant of triple approach, more become important topic of concern.
Cannabidiol (CBD) is that a kind of nontoxic of extraction from Fructus Cannabis floral leaf can be used for medicine, cosmetic
Product, the aldehydes matter of a kind of high added value of health food.At present, Israel, the U.S., Britain etc. are sent out
Reach country done raw material with it and developed multiple special effect medicine and cosmetics.CBD is the non-one-tenth in Fructus Cannabis
Addiction composition, can hinder THC to affect nerve system of human body, and have spasmolytic, antirheumatic joint
The pharmacologically actives such as inflammation, anxiety, also have the report in terms for the treatment of mental sickness, but are used alone Fructus Cannabis
The effect of diphenol (CBD) treatment depression is unsatisfactory.Therefore new activity is developed high, toxic and side effects
Little medicine seems the most necessary.
Summary of the invention
Present invention aims to the deficiencies in the prior art, it is provided that a kind of with industrial hemp for the most former
The pharmaceutical composition of the treatment depression of material preparation.
The purpose of the present invention is achieved by the following technical programs.
Except as otherwise noted, percent of the present invention is mass percent.
A kind of medicine treating depression, it is characterised in that be made up of the raw material blending of following weight parts:
Industrial hemp Fructus Cannabis extract 0.3 part～99.7 parts, industrial hemp Urtica cannabina L. element 99.7 parts～0.3 part.
The raw material composition of described medicament for treatment of depression is preferably industrial hemp Fructus Cannabis extract 40 parts
With industrial hemp Urtica cannabina L. element 60 parts.
Wherein, described industrial hemp Fructus Cannabis extract is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extract pulverizing Fructus Cannabis material with ethanol, concentration of alcohol
Being 95%～100% (V/V), solid-liquid ratio is 1:5～1:20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
When industrial hemp Fructus Cannabis being extracted with ethanol, following various ways can be used to carry out: as
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days；Under the conditions of 60～85 DEG C, heating
Extract 2 times, each 1～3 hour；Ultrasonic assistant extracts, ultrasonic frequency 30～60kHz, merit
Rate 100～1000W, extraction time 30～60min, extraction temperature 25～50 DEG C；Also microwave can be used
Other prior art such as assisted extraction.
Described industrial hemp Urtica cannabina L. element is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, eluting
Number of times is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
The flower of described industrial hemp, leaf, the optimum ratio of fiber crops bran three's mixture are 1:3:2.
Common Folium Cannabis, Flos Cannabis be respectively provided with toxicity (containing tetrahydrocannabinol THC marijuana hemp to the most unreal
Material).For getting rid of the toxicity of crude drug, present invention preferably employs the industrial hemp kind of Yunnan growth
Flower, leaf, fiber crops bran and the Fructus Cannabis of " cloud fiber crops No. 1 " are as raw material.By China's relevant legal documents rule
Fixed, " cloud fiber crops No. 1 " can only be planted within the border in Yunnan, and its flower, leaf, numb bran can only be in border, Yunnan
Interior processing.
The pharmaceutical composition of the present invention can make different pharmaceutical preparation further, including oral agents and pin
Agent, wherein oral agents includes capsule, oral liquid, tablet, drop pill, granule etc., and injection includes note
Penetrate liquor type and freeze-dried powder injection type etc..When preparing oral formulations, available auxiliary type agent is permissible
It it is the conventional filler such as starch, dextrin or cyclodextrin, sucrose, stearate.Lyophilized injectable powder can lead to
Prepared by the methods such as aseptic spray drying, low-temperature vacuum drying, lyophilization of crossing.Prepared by the later stage of each preparation
Processes and apparatus all belongs to the routine techniques of pharmaceutical field, and this is not construed as limiting by the present invention, therefore at this most in detail
State.
The pharmaceutical composition of the present invention has the effect of clear and definite treatment depression, and experiment finds, this medicine
The mouse tail suspension dead time that can make behavioral despair depression model all significantly reduces, the forced swimming dead time
All significantly reducing, effect is better than cannabidiol；Reserpine induced mice depression model is had the most anti-
Depressed effect, effect is better than cannabidiol；Being remarkably improved mice autonomic activities number of times, effect is better than greatly
Fiber crops diphenol.
Degradation under the learning memory of depression secondary is had by medicine of the present invention significantly alleviates work
With.Can be used for preparing treatment and include endogenous depression, reactive depression, masked depression, medicine
Secondary depression, climacteric or postpartum depression, cerebral trauma or the depression of apoplexy induction that thing causes
Disease, Patients with Diabetes Accompanied by Depression and depressive neurosis at the medicine of interior various depressive symptoms, and
The insecondary learning and memory caused for preparing treatment depression declines, the medicine of the symptoms such as anhedonia
Thing.
Detailed description of the invention
Below by embodiment, the present invention is described in further detail, but embodiment is not to this
The restriction of bright technical scheme.
Embodiment 1
Use flower, leaf, fiber crops bran and the Urtica cannabina L. of the industrial hemp kind " cloud fiber crops No. 1 " of Yunnan growth
Core is as raw material.Take maturation industrial hemp Fructus Cannabis, drying, remove impurity, standby after pulverizing；Use second
Alcohol to pulverize Fructus Cannabis material extract (under the conditions of 60～85 DEG C, heating extraction 2 times, each 1～
3 hours), concentration of alcohol is 95%～100% (V/V), and solid-liquid ratio is 1:5～1:20；Leach lixiviating solution,
Industrial hemp Fructus Cannabis extract it is after concentrating under reduced pressure.
Take the flower of industrial hemp, leaf, fiber crops bran 1:3:2 mass ratio mixture, drying, remove impurity,
It is crushed to 10～60 mesh；Supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is thrown
Enter in supercritical carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～
90min, extracting pressure 25～35Mpa, carbon dioxide flow 40kg/h, extraction is collected in separating still outlet
Thing；The extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, washing steps
It it is 1～3 time；Collect eluent, concentrating under reduced pressure, vacuum drying, after pulverizing, obtain industrial hemp Urtica cannabina L.
Element.
Take industrial hemp Fructus Cannabis extract 40 parts, industrial hemp Urtica cannabina L. element 60 parts, mixing, get Ben Fa
Bright medicine B.
Embodiment 2
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days.Take the flower of industrial hemp, leaf, fiber crops
The mixture of bran 1:1:1 mass ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 0.3 part, industrial hemp Urtica cannabina L. element 99.7 parts, mixing, obtain
Medicine A of the present invention.
Embodiment 3
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Employing ultrasonic assistant extracts, and ultrasonic frequency 30～60kHz, power 100～1000W, during extraction
Between 30～60min, extraction temperature 25～50 DEG C.Take the flower of industrial hemp, leaf, fiber crops bran 3:2:1 matter
The mixture of amount ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 99.7 parts, industrial hemp Urtica cannabina L. element 0.3 part, mixing, obtain
Medicine C of the present invention.
Embodiment 4
Example 1 gained medicine 100 grams (crosses 80 mesh sieves), adds 60 grams of microcrystalline Cellulose, crosses 80
Mesh sieve three times, mix homogeneously, spray into 95% ethanol solution, soft material processed, cross 40 mesh sieves and pelletize, 60 DEG C
It is dried half an hour, is sub-packed in 3# capsule, aluminium plastic composite packaging, prepare medicament for treatment of depression capsule.
Embodiment 5
Example 2 gained medicine, admixture doses 5～the dried starch of 20% and 1～the stearic acid of 5%
Magnesium etc., blended, pelletize, be dried, tabletting, prepare medicament for treatment of depression tablet.
Embodiment 6
The adjuvants such as Example 3 gained medicine, adds sucrose water and the preservative of convention amount, stabilizer.
Filtration, sterilizing, be distributed in 10mL bottle, make medicament for treatment of depression oral liquid.
Embodiment 7
Example 1 gained medicine, adds water for injection and dissolves, add 2.0 ‰ activated carbons, stir,
Filter, continue, with 0.45 μm, 0.22 μm microporous filter membrane classified filtering, to supplement water for injection, subpackage
In cillin bottle, lyophilization, recharge high-purity nitrogen, jump a queue, gland, packaging, prepared treatment presses down
Strongly fragrant disease drug injection.
The impact of Application Example 1 present invention desperate depression model test acquired on mouse tail suspension method.
Choose body weight 18～22g Kunming mouse 50, male and female half and half, be randomly divided into 5 groups, often group
10, i.e. model group, cannabidiol group, A, B, C group of the present invention.Cannabidiol group and of the present invention group
All dissolving with 0.5%CMC-Na or be suspended to required administration concentration, model group gives the 0.5 of equal volume
%CMC-Na, each group gastric infusion 7 days all continuously, once a day, last is tested after being administered 1h.
By single mice tail end (at the 2cm of tail tip) with adhesive plaster stick at outstanding boot (30cm × 30cm ×
25cm) in upper bracket so that it is become reversal of the natural order of things state, head, from bottom about 5cm, once hangs 2 mices,
Centre dividing plate separates.Mice is in order to overcome abnormal position and struggle activity, but movable a period of time goes out
Existing discontinuity is motionless, the disappointed state of display.The suspension time is 6min, and after statistics, in 4min, outstanding tail adds up
Dead time (the i.e. mice of motionless state stop struggle motionless or without any activity).Experimental result is shown in Table 1:
Table 1 present invention impact on rat force swimming test
| Group | Dosage (mg/Kg) | The outstanding tail dead time (second) |
| Model group | CMC-Na | 108.5±13.5 |
| Cannabidiol group | 20 | 73.2±12.7** |
| A group of the present invention | 20 | 63.8±12.8** |
| B group of the present invention | 20 | 60.7±14.6** |
| C group of the present invention | 20 | 65.7±11.5** |
Note: compare with model group, * * P ＜ 0.01.
Test result indicate that, compare with model group, the present invention respectively organizes the mice TST dead time and significantly drops
Low, it is better than cannabidiol.
The impact of Application Example 2 present invention desperate depression model acquired on mouse forced swimming test method
Choose body weight 18～22g Kunming mouse 50, male and female half and half, be randomly divided into 5 groups, often group
10, i.e. model group, cannabidiol group, A, B, C group of the present invention.Cannabidiol group and of the present invention group
All dissolving with 0.5%CMC-Na or be suspended to required administration concentration, model group gives equal volume
0.5%CMC-Na, each group gastric infusion 7 days all continuously, once a day, last is tested after being administered 1h.
Mice is placed individually in the cylindrical glass cylinder of high 20cm, diameter 14cm, depth of water 10cm in cylinder,
Water temperature (25 ± 2) DEG C, timing 6min after mice enters water, after record, in 4min, swimming is accumulative motionless
Time (refer to that mice stops struggling in water, or aobvious floating state, the most small limb motion is to keep
Head is kept afloat).Experimental result is shown in Table 2:
Table 2 present invention impact on Mouse Forced Swim Test
| Group | Dosage (mg/Kg) | Non-swimming time (second) |
| Model group | CMC-Na | 151.2±24.6 |
| Positive drug group (FH) | 10 | 109.3±13.9** |
| A group of the present invention | 20 | 88.8±16.5** |
| B group of the present invention | 20 | 87.3±12.8*** |
| C group of the present invention | 20 | 90.4±18.5** |
Note: compare with model group, * * P ＜ 0.01, * * * P ＜ 0.001.
Test result indicate that, compare with model group, the FST dead time that the present invention respectively organizes all significantly reduces,
It is better than cannabidiol.
Application Example 3 present invention impact on drug-induced depressive state
The compounds such as reserpine are mainly wrapped by the symptomes complice of monoamine transmitters induction animal in exhaustion brain
Include: temperature decline, blepharoptosis and movable suppression.The generation of these symptoms may reduce brain with reserpine
Interior monoamine transmitters. especially 5-hydroxy tryptamine (5-HT), and the knot that supervention 5-HT receptor sensitivity changes
Really.Monoamine transmitters system mainly includes 5-HT system, NE system and dopamine (DA) system, is pressing down
The pathogenesis of strongly fragrant disease plays an important role.5-HT, 5-HI-AA in Brain of Patients with Depression and cerebrospinal fluid,
NE equal size is all low than normal person.5-HT relates to the tune of emotion, sleep, vigilance, memory and appetite etc.
Joint, NE deficiency then may result in mental retardation.Monoamine oxidase, MAO (MAO) be monoamine transmitters (5-HT, NE,
DA) important inactivator, if this enzyme is suppressed, in making brain, monoamine transmitter contents increases, and this is to changing
Kind depression has positive effect.In 1950's, people are observing antihypertensive reserpine
During curative effect, find that this medicine of patient's long-term taking that there are about 10-15% can produce depressive symptom.Pharmacology later
Learning research display, the basic pharmacological action of reserpine is the monoamine neurotransmitter in exhaustion teleneuron vesicle, by
This proposes the monoamine hypothesis of depression. and thinking that synaptic space monoamine neurotransmitter reduces is the depressed machine occurred
Reason, and antidepressants are by blocking monoamine-reuptake or suppression monoamine oxidase, MAO (MAO), make mediator metabolism
Reduce and play antidepressant effect.
Choose body weight 18～22g Kunming mouse 120, male and female half and half, be randomly divided into 6 groups, often group
20, it is Normal group (distilled water), model group (reserpine 1mg/kg.d), cannabidiol
Group (20mg/kg.d), A, B, C group of the present invention (20mg/kg.d).Each group mice continuous gavage distillation
Water or relative medicine 6 days, in addition to Normal group, each group gives reserpine 1mg/kg, eyelid after 60min
Sagging, temperature decline, movable suppression after 180min.After next day, mice last was administered, 30min puts into mice
In open field test case, adapt to 2min, observe the level of mice, Vertical movements number of times in 4min subsequently,
I.e. creep grid number and stand number of times.
Mice open field test is creeped grid number and the impact of number of times of standing by each group of table 3
| Group | Dosage (mg/Kg) | Creep grid number | Stand number of times |
| Normal group | - | 56.57±11.86** | 17.98±3.83** |
| Model group | - | 13.40±4.66 | 2.65±0.49 |
| Cannabidiol group | 20 | 30.84±10.62* | 5.98±0.38* |
| A group of the present invention | 20 | 57.85±8.36**△ | 17.16±0.45**△ |
| B group of the present invention | 20 | 60.03±11.24**△ | 18.39±1.68**△ |
| C group of the present invention | 20 | 56.47±11.75**△ | 16.85±2.87**△ |
Note: compare with model group, * P < 0.05, * * P < 0.01；Compare with cannabidiol group,△P ＜ 0.05.
Test result indicate that, each group of the present invention has the most anti-pressing down to reserpine induced mice depression model
Yu Zuoyong, effect is better than cannabidiol group.
Application Example 4 present invention impact on mice autonomic activities
Choose body weight 18～22g Kunming mouse 120, male and female half and half, be randomly divided into 6 groups, often group
20, it is Normal group (distilled water), model group (reserpine 1mg/kg.d), cannabidiol
Group (20mg/kg.d), A, B, C group of the present invention (20mg/kg.d).Each group mice continuous gavage distillation
Water or relative medicine 6 days, in addition to normal group, each group is given reserpine 1mg/kg, blepharoptosis after 60min,
Temperature decline, movable suppression after 180min.After next day, mice last was administered, 30min puts into mice and independently lives
Dynamic instrument, the movable number of times in record 5min.
Each group of impact on mice autonomic activities number of times of table 4
| Group | Dosage (mg/Kg) | Autonomic activities number of times |
| Normal group | - | 94.74±20.88* |
| Model group | - | 58.55±13.35 |
| Cannabidiol group | 20 | 80.36±18.46* |
| A group of the present invention | 20 | 112.46±12.59**△ |
| B group of the present invention | 20 | 121.75±19.39**△ |
| C group of the present invention | 20 | 107.19±17.61** |
Note: compare with model group, * P < 0.05, * * P < 0.01；Compare with cannabidiol group,△P ＜ 0.05.
Test result indicate that, each group of the present invention is remarkably improved mice autonomic activities number of times, and effect is better than greatly
Fiber crops diphenol group.
Claims (6)
1. the medicine treating depression, it is characterised in that by the raw material blending system of following weight parts
Become: industrial hemp Fructus Cannabis extract 0.3 part～99.7 parts, industrial hemp Urtica cannabina L. element 99.7 parts～0.3
Part.
The medicine for the treatment of depression the most according to claim 1, it is characterised in that: described medicine
Raw material composition be preferably industrial hemp Fructus Cannabis extract 40 parts and industrial hemp Urtica cannabina L. element 60 parts.
The medicine for the treatment of depression the most according to claim 1, it is characterised in that: described work
Sparetime university's fiber crops Fructus Cannabis extract is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extract pulverizing Fructus Cannabis material with ethanol, concentration of alcohol
Being 95%～100% (V/V), solid-liquid ratio is 1:5～1:20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
The medicine for the treatment of depression the most according to claim 1, it is characterised in that: described work
Sparetime university's fiber crops Urtica cannabina L. element is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, eluting
Number of times is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
The medicine for the treatment of depression the most according to claim 4, it is characterised in that: described work
The flower of sparetime university fiber crops, leaf, the optimum ratio of fiber crops bran three's mixture are 1:3:2.
6., according to the medicine of the treatment depression described in claim 1 or 2 or 3 or 4 or 5, it is special
Levy and be: the kind of described industrial hemp is preferably " cloud fiber crops No. 1 ".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415926.6A CN105943618A (en) | 2016-06-14 | 2016-06-14 | Drug for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610415926.6A CN105943618A (en) | 2016-06-14 | 2016-06-14 | Drug for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943618A true CN105943618A (en) | 2016-09-21 |
Family
ID=56905456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610415926.6A Pending CN105943618A (en) | 2016-06-14 | 2016-06-14 | Drug for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943618A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951869A (en) * | 2016-10-14 | 2018-04-24 | 汉义生物科技（北京）有限公司 | Pharmaceutical preparation and its application containing cannabidiol |
| CN108078984A (en) * | 2016-11-23 | 2018-05-29 | 汉义生物科技（北京）有限公司 | The composition and its application of serotonin and norepinephrine reuptake inhibitors and cannabidiol |
| CN108143726A (en) * | 2016-12-02 | 2018-06-12 | 汉义生物科技（北京）有限公司 | Cannabidiol and 5-HT2AThe medical composition and its use of receptor antagonist and 5-HT reuptaking inhibitors |
| CN108968071A (en) * | 2018-09-26 | 2018-12-11 | 江西中医药大学 | The application of bitter orange flower and fructus cannabis composition in preparation improvement failure of memory or medicament for treatment of depression or health functional beverage |
| CN113398104A (en) * | 2021-07-14 | 2021-09-17 | 北京森宏健康科技有限公司 | Use of cannabidiol in the treatment of bilirubin encephalopathy |
| WO2022058581A1 (en) * | 2020-09-19 | 2022-03-24 | Dmas B.V. | Method for treating hemp and product obtained |
| CN114392260A (en) * | 2022-02-15 | 2022-04-26 | 重庆市九龙坡区精神卫生中心(重庆市九龙坡区石坪桥医院) | Medicine for relieving anxiety and depression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
-
2016
- 2016-06-14 CN CN201610415926.6A patent/CN105943618A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
Non-Patent Citations (1)
| Title |
|---|
| 赵翾等: "响应面法优化火麻仁黄酮提取工艺", 《食品科学》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107951869A (en) * | 2016-10-14 | 2018-04-24 | 汉义生物科技（北京）有限公司 | Pharmaceutical preparation and its application containing cannabidiol |
| CN108078984A (en) * | 2016-11-23 | 2018-05-29 | 汉义生物科技（北京）有限公司 | The composition and its application of serotonin and norepinephrine reuptake inhibitors and cannabidiol |
| CN108078984B (en) * | 2016-11-23 | 2020-11-20 | 汉义生物科技（北京）有限公司 | Composition of 5-hydroxytryptamine and norepinephrine reuptake inhibitor and cannabidiol and application thereof |
| CN108143726A (en) * | 2016-12-02 | 2018-06-12 | 汉义生物科技（北京）有限公司 | Cannabidiol and 5-HT2AThe medical composition and its use of receptor antagonist and 5-HT reuptaking inhibitors |
| CN108143726B (en) * | 2016-12-02 | 2020-05-08 | 汉义生物科技（北京）有限公司 | Pharmaceutical composition of cannabidiol and 5-HT2A receptor antagonist and 5-HT reuptake inhibitor and application thereof |
| CN108968071A (en) * | 2018-09-26 | 2018-12-11 | 江西中医药大学 | The application of bitter orange flower and fructus cannabis composition in preparation improvement failure of memory or medicament for treatment of depression or health functional beverage |
| WO2022058581A1 (en) * | 2020-09-19 | 2022-03-24 | Dmas B.V. | Method for treating hemp and product obtained |
| CN113398104A (en) * | 2021-07-14 | 2021-09-17 | 北京森宏健康科技有限公司 | Use of cannabidiol in the treatment of bilirubin encephalopathy |
| CN114392260A (en) * | 2022-02-15 | 2022-04-26 | 重庆市九龙坡区精神卫生中心(重庆市九龙坡区石坪桥医院) | Medicine for relieving anxiety and depression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105943618A (en) | Drug for treating depression | |
| CN104435775A (en) | Chinese medicinal health-care spirit and preparation method thereof | |
| CN102344876A (en) | Nine-medicine Shengzi red fruit wine and preparation method thereof | |
| CN102293273A (en) | Health tea capable of adjusting blood pressure, blood sugar and blood fat and preventing thrombus and apoplexy | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN101502627A (en) | Chinese medicine health product preparation for preventing and treating alcoholic liver disease and preparation method thereof | |
| CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
| CN105963359A (en) | Application of all-cannabinoid in preparation of drugs for treating depression | |
| CN105935374A (en) | Application of Quanmasu in preparation of drugs for treatment of diabetes | |
| CN105943613A (en) | Application of whole hemp extract in preparation of drug for preventing and controlling cardiovascular and cerebrovascular diseases | |
| CN106074707A (en) | The application in pancreatitic medicine is treated in preparation of the general anesthesia element | |
| CN105943619A (en) | Application of whole hemp extract in preparation of drug for preventing and treating Alzheimer's disease | |
| CN105998194A (en) | Antithrombotic medicine | |
| CN105963355A (en) | Medicine for preventing and treating senile dementia | |
| CN105998192A (en) | Application of industrial cannabinoid in preparing drugs for treating gouty arthritis | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN106389535A (en) | Application of industrial hemp cannaboid in preparing gout treating medicines | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN105998191A (en) | Application of general anesthetic to preparation of drugs for treating gout | |
| CN106074710A (en) | A kind of medicine treating epilepsy | |
| CN105935375A (en) | Application of Quanmasu in preparation of anti-aging drugs | |
| CN105920104A (en) | Age-defying drug | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN102973726B (en) | Chinese patent drug for treating hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Chenfeng Inventor after: Hu Chengyue Inventor before: Chen Tianrui Inventor before: Hu Chengyue |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |